BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30388199)

  • 1. The prothrombotic state in atrial fibrillation: pathophysiological and management implications.
    Khan AA; Lip GYH
    Cardiovasc Res; 2019 Jan; 115(1):31-45. PubMed ID: 30388199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endothelium and atrial fibrillation. The prothrombotic state revisited.
    Freestone B; Lip GY
    Hamostaseologie; 2008 Oct; 28(4):207-12. PubMed ID: 18836646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited.
    Watson T; Shantsila E; Lip GY
    Lancet; 2009 Jan; 373(9658):155-66. PubMed ID: 19135613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis of thromboembolism in association with atrial fibrillation.
    Yamashita T
    Circ J; 2007; 71 Suppl A():A40-4. PubMed ID: 17587738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does heart failure confer a hypercoagulable state? Virchow's triad revisited.
    Lip GY; Gibbs CR
    J Am Coll Cardiol; 1999 Apr; 33(5):1424-6. PubMed ID: 10193748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anticoagulation in atrial fibrillation. Strategies in special situations].
    Volkmann H; Walter M; Walter C; Vetter S
    Clin Res Cardiol Suppl; 2011 May; 6():58-65. PubMed ID: 22528179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillation and the prothrombotic state: revisiting Virchow's triad in 2020.
    Ding WY; Gupta D; Lip GYH
    Heart; 2020 Oct; 106(19):1463-1468. PubMed ID: 32675218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolytic function and atrial fibrillation.
    Marín F; Roldán V; Lip GY
    Thromb Res; 2003 Mar; 109(5-6):233-40. PubMed ID: 12818244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Role of Coagulation, Fibrinolytic, and Endothelial Markers in Patients with Atrial Fibrillation, Stroke, and Thromboembolism: A Meta-Analysis, Meta-Regression, and Systematic Review.
    Weymann A; Sabashnikov A; Ali-Hasan-Al-Saegh S; Popov AF; Jalil Mirhosseini S; Baker WL; Lotfaliani M; Liu T; Dehghan H; Yavuz S; de Oliveira Sá MP; Jang JS; Zeriouh M; Meng L; D'Ascenzo F; Deshmukh AJ; Biondi-Zoccai G; Dohmen PM; Calkins H; Cardiac Surgery And Cardiology-Group Imcsc-Group IM
    Med Sci Monit Basic Res; 2017 Mar; 23():97-140. PubMed ID: 28360407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic options for atrial fibrillation in 2012.
    Rude J; Quevedo K; Rodriguez de Armas L; Mukherjee D
    Cardiovasc Hematol Disord Drug Targets; 2012 Sep; 12(1):1-5. PubMed ID: 22524172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation.
    Conway DS; Buggins P; Hughes E; Lip GY
    Am J Cardiol; 2004 Jun; 93(11):1368-73, A6. PubMed ID: 15165916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.
    Lip GY; Laroche C; Popescu MI; Rasmussen LH; Vitali-Serdoz L; Dan GA; Kalarus Z; Crijns HJ; Oliveira MM; Tavazzi L; Maggioni AP; Boriani G
    Europace; 2015 Dec; 17(12):1777-86. PubMed ID: 26321406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data.
    Hughes M; Lip GY;
    Thromb Haemost; 2008 Feb; 99(2):295-304. PubMed ID: 18278178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism and risk factors of cardiogenic thromboembolism in patients with atrial fibrillation].
    Otsuka T
    Nihon Rinsho; 2013 Jan; 71(1):36-40. PubMed ID: 23631169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology, anticoagulant treatment and risk of thromboembolism in patients with valvular atrial fibrillation: Results from Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER).
    Kaya H; Ertaş F; Kaya Z; Kahya Eren N; Yüksel M; Köroğlu B; Köse N; Yıldız A; Cimen T; Ulgen MS
    Cardiol J; 2014; 21(2):158-62. PubMed ID: 23799558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
    Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
    Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.